These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

333 related articles for article (PubMed ID: 33935082)

  • 1. The Association Between Second-Line Oral Antihyperglycemic Medication on Types of Dementia in Type 2 Diabetes: A Nationwide Real-World Longitudinal Study.
    Kim WJ; Noh JH; Han K; Park CY
    J Alzheimers Dis; 2021; 81(3):1263-1272. PubMed ID: 33935082
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Important differences in the durability of glycaemic response among second-line treatment options when added to metformin in type 2 diabetes: a retrospective cohort study.
    Mamza J; Mehta R; Donnelly R; Idris I
    Ann Med; 2016; 48(4):224-34. PubMed ID: 26982210
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Second-line glucose-lowering drugs added to metformin and the risk of hospitalization for heart failure: A nationwide cohort study.
    Lee SJ; Ha KH; Lee JH; Lee H; Kim DJ; Kim HC
    PLoS One; 2019; 14(2):e0211959. PubMed ID: 30742667
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intensification with dipeptidyl peptidase-4 inhibitor, insulin, or thiazolidinediones and risks of all-cause mortality, cardiovascular diseases, and severe hypoglycemia in patients on metformin-sulfonylurea dual therapy: A retrospective cohort study.
    Wong CKH; Man KKC; Shi M; Chan EW; Ho CW; Tse ETY; Wong ICK; Lam CLK
    PLoS Med; 2019 Dec; 16(12):e1002999. PubMed ID: 31877127
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cardiovascular events associated with second-line anti-diabetes treatments: analysis of real-world Korean data.
    Ha KH; Kim B; Choi H; Kim DJ; Kim HC
    Diabet Med; 2017 Sep; 34(9):1235-1243. PubMed ID: 28523719
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Progression to insulin for patients with diabetes mellitus on dual oral antidiabetic therapy using the US Department of Defense Database.
    Rascati K; Richards K; Lopez D; Cheng LI; Wilson J
    Diabetes Obes Metab; 2013 Oct; 15(10):901-5. PubMed ID: 23531154
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Glitazones and alpha-glucosidase inhibitors as the second-line oral anti-diabetic agents added to metformin reduce cardiovascular risk in Type 2 diabetes patients: a nationwide cohort observational study.
    Chan CW; Yu CL; Lin JC; Hsieh YC; Lin CC; Hung CY; Li CH; Liao YC; Lo CP; Huang JL; Lin CH; Wu TJ
    Cardiovasc Diabetol; 2018 Jan; 17(1):20. PubMed ID: 29368615
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Risk of fractures and diabetes medications: a nationwide cohort study.
    Choi HJ; Park C; Lee YK; Ha YC; Jang S; Shin CS
    Osteoporos Int; 2016 Sep; 27(9):2709-2715. PubMed ID: 27080708
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of dipeptidyl peptidase IV inhibitors, thiazolidinedione, and sulfonylurea on osteoporosis in patients with type 2 diabetes: population-based cohort study.
    Yang BR; Cha SH; Lee KE; Kim JW; Lee J; Shin KH
    Osteoporos Int; 2021 Sep; 32(9):1705-1712. PubMed ID: 33594487
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Risk of overall mortality and cardiovascular events in patients with type 2 diabetes on dual drug therapy including metformin: A large database study from the Cleveland Clinic.
    Kannan S; Pantalone KM; Matsuda S; Wells BJ; Karafa M; Zimmerman RS
    J Diabetes; 2016 Mar; 8(2):279-85. PubMed ID: 25929426
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Progression to insulin for patients with diabetes mellitus using the Texas Medicaid database.
    Rascati KL; Richards KM; Lopez D; Cheng LI; Wilson JP
    Clin Ther; 2011 Dec; 33(12):2016-20. PubMed ID: 22101160
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cardiovascular safety of glucose-lowering agents as add-on medication to metformin treatment in type 2 diabetes: report from the Swedish National Diabetes Register.
    Ekström N; Svensson AM; Miftaraj M; Franzén S; Zethelius B; Eliasson B; Gudbjörnsdottir S
    Diabetes Obes Metab; 2016 Oct; 18(10):990-8. PubMed ID: 27282621
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dipeptidyl peptidase-4 inhibitors in triple oral therapy regimens in patients with type 2 diabetes mellitus.
    Barnett AH; Charbonnel B; Moses RG; Kalra S
    Curr Med Res Opin; 2015; 31(10):1919-31. PubMed ID: 26361231
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Retrospective analysis of long-term adherence to and persistence with DPP-4 inhibitors in US adults with type 2 diabetes mellitus.
    Farr AM; Sheehan JJ; Curkendall SM; Smith DM; Johnston SS; Kalsekar I
    Adv Ther; 2014 Dec; 31(12):1287-305. PubMed ID: 25504156
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Use of oral diabetes medications and the risk of incident dementia in US veterans aged ≥60 years with type 2 diabetes.
    Tang X; Brinton RD; Chen Z; Farland LV; Klimentidis Y; Migrino R; Reaven P; Rodgers K; Zhou JJ
    BMJ Open Diabetes Res Care; 2022 Sep; 10(5):. PubMed ID: 36220195
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Metformin combined with dipeptidyl peptidase-4 inhibitors or metformin combined with sulfonylureas in patients with type 2 diabetes: A real world analysis of the South Korean national cohort.
    Cho YY; Cho SI
    Metabolism; 2018 Aug; 85():14-22. PubMed ID: 29530797
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of antidiabetic agents on dementia risk: A Bayesian network meta-analysis.
    Zhou JB; Tang X; Han M; Yang J; Simó R
    Metabolism; 2020 Aug; 109():154265. PubMed ID: 32446679
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects on Clinical Outcomes of Adding Dipeptidyl Peptidase-4 Inhibitors Versus Sulfonylureas to Metformin Therapy in Patients With Type 2 Diabetes Mellitus.
    Ou SM; Shih CJ; Chao PW; Chu H; Kuo SC; Lee YJ; Wang SJ; Yang CY; Lin CC; Chen TJ; Tarng DC; Li SY; Chen YT
    Ann Intern Med; 2015 Nov; 163(9):663-72. PubMed ID: 26457538
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment persistence, hypoglycaemia and clinical outcomes in type 2 diabetes patients with dipeptidyl peptidase-4 inhibitors and sulphonylureas: a primary care database analysis.
    Rathmann W; Kostev K; Gruenberger JB; Dworak M; Bader G; Giani G
    Diabetes Obes Metab; 2013 Jan; 15(1):55-61. PubMed ID: 22862879
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The association of antidiabetic medications and Mini-Mental State Examination scores in patients with diabetes and dementia.
    Secnik J; Xu H; Schwertner E; Hammar N; Alvarsson M; Winblad B; Eriksdotter M; Garcia-Ptacek S; Religa D
    Alzheimers Res Ther; 2021 Dec; 13(1):197. PubMed ID: 34857046
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.